

- 1) Jindani A, Harrison TS, Nunn AJ, Phillips PPJ, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson ALE, McHugh TD, Butcher PD, Mitchison DA. 2014. High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. *N. Engl. J. Med.* 371:1599–1608.
- 2) Dawson R, Narunsky K, Carman D, Gupte N, Whitelaw A, Efron A, Barnes GL, Hoffman J, Chaisson RE, McIlleron H, Dorman SE. 2015. Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis. *Int. J. Tuberc. Lung Dis.* 19:780–786.
- 3) Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JHM, Huitema ADR. 2012. Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses. *AAPS J* 14:601–611.